STAT

Opinion: Deaths of despair can be prevented with a comprehensive strategy

The U.S. needs a comprehensive strategy to stem the rising tide of suicide, drug-related deaths, and other deaths of despair.
A child plays beside a message board in Sawyer Point Park in Cincinnati, Ohio, that is adorned with notes for loved ones who took their own lives.

Far too many Americans are dying from preventable causes, and each time we make progress it seems like new problems appear. Take the case of opioid overdoses. As we are beginning to get a handle on misuse of prescription opioids, fentanyl and synthetic opioids have come to the fore. Two decades ago, they were linked to fewer than 1,000 deaths each year. In 2017, fentanyl and synthetic opioids killed more than 28,000 Americans.

The emphasis on opioids is appropriate, but too narrow. The underlying conditions that often lead to drug misuse can also lead to alcohol misuse, loneliness, and despair. Even

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A 486% Drug Price Hike, AstraZeneca CEO Pay, And More
Is there any circumstance when a 486% increase for a medicine might be justified? A small company called Harrow argues the case for an injectable eye treatment.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks